Biocon Q3 ke liye taiyaar, Biosimilar sales badhne ki ummeed

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Biocon Q3 ke liye taiyaar, Biosimilar sales badhne ki ummeed
Overview

Biocon Q3FY26 mein zabardast performance ke liye ready hai, jisme biosimilars growth ko lead karega. Analysts ko bStelara jaise key products aur emerging markets se revenue growth ki expectation hai. Generics segment bhi naye launches ke saath promising dikh raha hai, lekin competition bhi hai. Ye BBL consolidation ke baad pehla result hoga, jisme topline 18% badhne ka andaza hai.

Biosimilar Momentum

Ye quarter Biocon Biologics Ltd (BBL) ka integration ke baad pehla consolidated view dega, jisme overall topline 18% badhne ki expectation hai. Core biosimilar sales $315 million tak pahunchne ka forecast hai, jo ki 23% year-on-year increase hai. Ye surge key products, jisme United States market mein bStelara ka ongoing ramp-up aur emerging markets mein behtar traction shamil hai, ke market share gains ke karan hai.

Generics Segment Outlook

Generics division mein, Kotak Institutional Equities ne 17% year-on-year growth estimate ki hai. Ye largely United Kingdom aur European markets mein Liraglutide launch ke fayde se support hai. Syngene, jo contract research arm hai, se 4% year-on-year revenue increase ki projection hai.

Divergent Brokerage Views

Jabki kai log strong results ki ummeed kar rahe hain, Axis Securities ne thoda alag nazariya pesh kiya hai. Unhone research segment mein 7% YoY growth forecast ki hai aur generics business par badhti competition ke karan pressure anticipate kiya hai. Halanki, Axis Securities ne yeh bhi project kiya hai ki Insulin Aspart, Yesafili, Denosumab biosimilars, aur UK mein Liraglutide jaise naye launches se chalte hue biosimilar revenue lagbhag 18% year-on-year badhega.

Margin Improvements

Biosimilars business ke liye gross margins mein 100 basis points quarter-on-quarter improvement dekhne ki ummeed hai, jo 65% tak pahunch jayega. Iske parinaam swaroop, biosimilars segment ke liye EBITDA 31% year-on-year badhkar ₹980 crore hone ka project kiya gaya hai. Investors BBL ke integration aur future product pipelines ke strategic outlook ke baare mein management commentary ko dhyan se sunenge.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.